Biltmore Family Office’s Heron Therapeutics HRTX Stock Holding History

Biltmore Family Office’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80K	Hold	100,000	–	–	0.01%	264
2025 Q4	$130K	Hold	100,000	–	–	0.02%	242
2025 Q3	$126K	Sell	100,000 -1,467	-1%	-$2.33K	0.02%	225
2025 Q2	$210K	Hold	101,467	–	–	0.04%	204
2025 Q1	$223K	Hold	101,467	–	–	0.04%	195
2024 Q4	$155K	Buy	+101,467	New	+$164K	0.03%	208
2023 Q4	–	Sell	-16,425	Closed	-$16.9K	–	237
2023 Q3	$16.9K	Hold	16,425	–	–	﹤0.01%	213
2023 Q2	$19.1K	Buy	16,425 +125	+0.8%	+$223	﹤0.01%	210
2023 Q1	$24.6K	Buy	+16,300	New	+$40.8K	0.01%	249

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Biltmore Family Office's HRTX Position: Q1 2026 in Review

Biltmore Family Office held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 100,000 shares worth $80K. The position accounts for 0.01% of the portfolio, ranked #264.

Biltmore Family Office first reported a position in HRTX in Q1 2023 and has held it in 9 quarters since. The position peaked at $223K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

Biltmore Family Office held 100,000 shares of Heron Therapeutics worth $80K as of Q1 2026.
Biltmore Family Office left its Heron Therapeutics share count unchanged in Q1 2026.
Heron Therapeutics made up 0.01% of Biltmore Family Office's portfolio in Q1 2026, its #264 holding.
Biltmore Family Office first reported a position in Heron Therapeutics in Q1 2023 and has held it in 9 quarters since.
Biltmore Family Office's Heron Therapeutics position peaked at $223K in Q1 2025.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Biltmore Family Office's 13F filing for Q1 2026, filed 11 May 2026.